Value through Innovation28 April 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
22.04.2015

2014: Boehringer Ingelheim positioned for future growth with product launches

17.04.2015

New international survey of lung cancer oncologists highlights underutilization of personalized treatments

- For media outside the US, the UK and Canada only
13.04.2015

Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders

30.03.2015

Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union

- For media outside the US, the UK and Canada only
20.03.2015

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

 

- For Non-UK / Non-Canadian Media only
16.03.2015

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

- For Non-US/Non-UK/Non-Canadian Media
12.03.2015

EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe

03.03.2015

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

- For Non-US/Non-UK Media
02.03.2015

Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela® in Europe

24.02.2015

Boehringer Ingelheim Animal Health continues support of independent PCV2 research

27.01.2015

New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD

- For media outside the US, the UK and Canada
19.01.2015

OFEV® (nintedanib*) approved in the EU for the treatment of IPF

- For media outside UK, US and Canada
15.01.2015

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals

15.01.2015

35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia

14.01.2015

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

13.01.2015

Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas

12.01.2015

The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy

- For media outside UK, US and Canada only
22.12.2014

New vaccine against Bovine Viral Diarrhea: Boehringer Ingelheim receives European marketing authorization for Bovela®

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16